SCHEMBL25416299

SCHEMBL25416299

c1cn2c(-c3ccc4c(c3)CCCC4)nnc2cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 4/20 0.49
CYP11B2 P19099 4/20 0.49
PDE2A O00408 1/20 0.41
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
SIGMAR1 Q99720 2/20 0.38
MAPT P10636 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KMT2A Q03164 2/20 0.35
HSD17B10 Q99714 2/20 0.35
TP53 P04637 2/20 0.35
HPGD P15428 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MEN1 O00255 1/20 0.35
ALOX15 P16050 1/20 0.35
TMEM97 Q5BJF2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL108966 0.74 PDE2A (0.49) PDE2AKDM4EALDH1A1L3MBTL1MAPK1
SCHEMBL2357430 0.73 KDM4E (0.61) PDE2AKDM4EALDH1A1MAPK1MAPT
SCHEMBL30498955 0.72 KDM4E (0.47) PDE2AKDM4EALDH1A1L3MBTL1MAPK1
SCHEMBL2023340 0.71 KDM4E (0.45) CYP11B1CYP11B2PDE2AKDM4EALDH1A1
SCHEMBL2021844 0.71 ALDH1A1 (0.43) CYP11B1CYP11B2PDE2AKDM4EALDH1A1
SCHEMBL29972563 0.71 GAA (0.51) PDE2AKDM4EALDH1A1L3MBTL1MAPK1
SCHEMBL23832439 0.67 DRD1 (0.37) CYP11B1CYP11B2ALDH1A1SIGMAR1MAPT
SCHEMBL8081400 0.66 CYP11B2 (1.00) CYP11B1CYP11B2ALDH1A1CYP3A4CYP17A1
SCHEMBL28663639 0.65 CYP11B1 (0.61) CYP11B1CYP11B2KDM4EALDH1A1L3MBTL1
SCHEMBL23641045 0.65 CYP11B2 (0.62) CYP11B1CYP11B2ALDH1A1SIGMAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150929-A1 SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 UNIV TEXAS (US) 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150929-A1 SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 CREB1, RAPGEF4, ATF4 CYP11B1 2539/4885CYP11B2 2715/4885PDE2A 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.